Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024

The glioblastoma multiforme (gbm) treatment market size has grown rapidly in recent years. It will grow from $2.23 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The increase during the historical period can be credited to the increased incidence and prevalence of the condition, advancements in diagnostic techniques, funding for clinical trials and research, collaborations and partnerships in the medical field, and an enhanced understanding of tumor biology.

The glioblastoma multiforme (gbm) treatment market size is expected to see rapid growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The anticipated growth in the forecast period can be ascribed to the emergence of immunotherapies, advancements in precision medicine, an expanded understanding of genetic markers, increased patient advocacy and awareness, and government support for rare diseases. Key trends expected in the forecast period encompass the exploration of combination therapies, the integration of artificial intelligence in diagnosis and treatment planning, a rise in the adoption of immunotherapeutic approaches, and advancements in medical tools and equipment.

The growth of the glioblastoma multiforme (GBM) treatment market is expected to be fueled by the increasing prevalence of brain disorders. Brain disorders, including GBM, result from various factors such as aging populations, compromised immune systems, overdiagnosis, ionizing radiation, and air pollution. The need for treating brain disorders has intensified due to their impact on well-being. Globally, approximately 308,102 cancer cases related to the brain and central nervous system were detected in 2020, according to Globocan. The American Cancer Society estimates around 25,050 new malignant tumors of the brain or spinal cord cancer cases in the US in 2022. Thus, the rising prevalence of brain disorders is a key driver of the GBM treatment market.

The glioblastoma multiforme (GBM) treatment market is expected to grow due to the rising geriatric population. The elderly, aged 65 and older, present specific health considerations, leading to the development of treatment strategies tailored for older patients with GBM. According to the World Health Organization, by 2030, 1 in 6 individuals globally will be 60 or older, reaching 2.1 billion elderly people by 2050. This demographic shift is a key factor propelling the growth of the GBM treatment market.

Advancements in therapies are gaining popularity as major companies invest in research and development for innovative treatments. In November 2021, Daiichi Sankyo Company Limited, a Japanese pharmaceutical company, launched DELYTACT, the first oncolytic virus-based immunotherapy (Teserpaturev) in collaboration with the Institute of Medical Science, The University of Tokyo. DELYTACT uses genetically modified viruses to infect and replicate in cancer cells, triggering multiple mechanisms of the patient's immune system to produce immune-boosting molecules and initiate anti-cancer immunity.

Major companies are prioritizing innovative treatments such as radiopharmaceutical therapy to meet the demand for advanced and targeted therapeutic solutions. Radiopharmaceutical therapy involves using radioactive substances to deliver targeted radiation to specific tissues or cells, commonly employed in cancer treatment to destroy cancer cells. For instance, in February 2022, Theragnostics, a UK-based provider of molecular radiotherapy and molecular imaging diagnostic products, announced the development of I-123 PARPi (THG-009) therapy. This innovative therapy, granted an Innovation Passport by the UK MHRA, aims to address primary and recurrent Glioblastoma Multiforme (GBM) and is advancing to a Phase 1 clinical trial.

In April 2022, Elekta, a Sweden-based company providing radiation therapy, radiosurgery, related equipment, and clinical management for cancer treatment, signed a global commercial collaboration agreement with GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals. This collaboration enables them to offer comprehensive solutions across imaging and treatment for cancer patients requiring radiation therapy. The partnership facilitates the joint promotion of solutions tailored to the needs of each cancer center.

Major companies operating in the glioblastoma multiforme (gbm) treatment market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Carl Zeiss AG, Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Arbor Pharmaceuticals LLC, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc., Angiochem Inc., Diffusion Pharmaceuticals Inc.

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glioblastoma multiforme (gbm) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary treatments for glioblastoma multiforme (GBM) include surgery, radiation therapy, chemotherapy, targeted therapy, tumor-treating field (TTF) therapy, and immunotherapy. Surgery is a medical discipline that concentrates on employing manual and instrumental methods to treat wounds, illnesses, and other conditions. The types of drugs involved in GBM treatment include temozolomide, bevacizumab, lomustine, carmustine wafers, and others. These medications are administered through oral, parenteral, and various other routes of administration and are used by hospitals, clinics, and ambulatory surgical centers.

The glioblastoma multiforme (GBM) treatment market research report is one of a series of new reports that provides glioblastoma multiforme (GBM) treatment market statistics, including glioblastoma multiforme (GBM) treatment industry global market size, regional shares, competitors with glioblastoma multiforme (GBM) treatment market share, detailed glioblastoma multiforme (GBM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (GBM) treatment industry. This glioblastoma multiforme (GBM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.